Emcure Pharmaceuticals Ltd on Wedneday made a fabulous listing with a premium of 31 per cent.
As against IPO price of ₹1,008, the pharma major stock listed at ₹1,325.05 on the BSE and rose to a high of ₹1,384. However, profit taking dragged the stock to close at ₹1,358.85, up 34.81 per cent.
The IPO received an overwhelming response, especially from qualified institutional buyers.
The Bain Capital-backed Emcure Pharma IPO at a price band of ₹960-1,008 was subscribed 67.87 times. Emcure Pharma hit the market with an IPO size of ₹1,952.03 crore - a fresh issue of 79 lakh shares worth ₹800 crore, and an offer-for-sale (OFS) of 1.14 crore shares totalling ₹1,152.03 crore.
Namita Thapar, one of the pharma major’s promoters, sold over 12.68 lakh shares through offer-for-sale (OFS). Other promoters, Satish Ramanlal Mehta, Sunil Rajanikant Mehta and Samit Satish Mehta offloaded part of their stake in the OFS. BC Investments IV Ltd, an affiliate of US-based private equity major Bain Capital, was also among the shares in the OFS.
As part of its IPO, Emcure Pharmac raised over ₹582 crore from anchor investors.
The pharma company plans to use the net proceeds to repay and/ or prepay all or part of certain outstanding borrowings and for general corporate purposes.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.